Miniatura

Fitxers

699472.pdf (587.21 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-02-12

Llicència de publicació

cc-by-nc (c) Ortiz Romero, Pablo Luis et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/173771

Cost of early-stage mycosis fungoides treatments in Spain

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.2147/CEOR.S233376

Resum

Aim: To identify the most common therapeutic options for the treatment of early-stage mycosis fungoides in Spain, quantify their associated healthcare resource use and costs. Methods: After reviewing the literature, a panel of 6 Spanish clinical dermatologists validated the treatments and healthcare resource use through a structured questionnaire. Individual responses were collected, analyzed and presented into a face-to-face meeting in order to reach a consensus. Cost categories considered were: drug acquisition and administration, photo/radiotherapy session and maintenance, clinical follow-up visits and laboratory tests. Costs were expressed in euros from 2018. The Spanish National Health System perspective was considered, taking into account direct health costs and time horizons of 1, 3 and 6 months. Results: Costs for the skin-directed treatments (SDT) assessed at 1, 3 and 6 months, were: Topical carmustine [ 6,593.36, 19,780.09 and 27,592.78]; Phototherapy with psoralens and ultraviolet A light (PUVA) [ 1,098.68, 2,999.99 and 3,187.60]; Narrow-band ultraviolet B phototherapy [ 1,657.47, 4,842.10 and 4,842.10]; Total skin electron beam therapy (TSEBT) [ 6,796.45, 7,913.34 and 7,913.34]. Cost for topical corticosteroids, being considered an adjuvant option, were 17.16, 51.49 and 102.97. Costs for the assessed systemic treatments alone or in combination with SDT at 1, 3 and 6 months, were: Systemic retinoids [ 2,026.03, 5,206.63 and 7,426.42]; Systemic retinoids + PUVA phototherapy [ 3,066.50, 8,271.26 and 10,046.58]; Interferon alfa + PUVA phototherapy [ 1,541.09, 5,167.57 and 6,404.55]. Conclusion: According to the Spanish clinical practice, phototherapies in monotherapy were the treatments with the lowest associated costs regardless of the time horizon considered. TSEBT turned out as the treatment with the highest associated costs when considering 1 month. However, while considering 3 and 6 months the treatment with the highest associated costs was topical carmustine. The results of this analysis may provide critical information to measure the disease burden, to detect unmet medical needs and to advocate towards better treatments for this rare disease.

Matèries

Micosi, Enquestes, Salut, Malalties rares

Matèries (anglès)

Mycosis, Surveys, Health, Rare diseases

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

ORTIZ ROMERO, Pablo luis, SERVITJE, Octavio, ESTRACH PANELLA, Ma. teresa (maría teresa), IZU BELLOSO, Rosa maría, FERNÁNDEZ DE MISA, Ricardo, GALLARDO, F. (fernando), LÓPEZ MARTÍNEZ, Noemí, PÉREZ MITRU, Alejandro. Cost of early-stage mycosis fungoides treatments in Spain. _Clinicoeconomics and Outcomes Research_. 2020. Vol. 12, núm. 91-105. [consulta: 2 de febrer de 2026]. ISSN: 1178-6981. [Disponible a: https://hdl.handle.net/2445/173771]

Exportar metadades

JSON - METS

Compartir registre